8-KLeadership ChangesRegulation FDExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Executive Changes (Jun 10, 2015)

Filed June 10, 2015For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) announced on June 10, 2015, that David-Alexandre Gros, M.D., was appointed as Senior Vice President and Chief Business Officer, effective June 8, 2015. Dr. Gros brings extensive experience from his previous role as Executive Vice President and Chief Strategy Officer at Sanofi, where he was involved in corporate strategy, business development, licensing, and M&A. His background also includes significant experience in investment banking and consulting within the pharmaceutical sector. This appointment is a strategic move by Alnylam to bolster its leadership team with seasoned expertise in business development and strategy, which is crucial for a biotechnology company focused on drug pipeline advancement and potential partnerships. Investors should view this as a positive development, indicating the company's commitment to strengthening its corporate development capabilities as it progresses its therapeutic candidates.

Key Highlights

  • 1Appointment of David-Alexandre Gros, M.D. as Senior Vice President, Chief Business Officer, effective June 8, 2015.
  • 2Dr. Gros' prior experience includes Executive Vice President and Chief Strategy Officer at Sanofi.
  • 3His responsibilities at Sanofi covered corporate strategy, business development, licensing, M&A, and alliance management.
  • 4Dr. Gros also has a background in investment banking (Centerview Partners, Merrill Lynch) and consulting (McKinsey & Co.).
  • 5Compensation includes an annual base salary of $425,000, a sign-on bonus of $200,000, and an additional $100,000 bonus after one year.
  • 6Dr. Gros is eligible for an annual cash bonus targeted at 40% of base salary and a stock option grant for 140,000 shares at an exercise price of $129.97.
  • 7The stock option vests over four years, with 25% on the first anniversary and the remainder ratably over the subsequent three years.

Frequently Asked Questions

Dr. Gros' appointment as Chief Business Officer is significant as it brings seasoned leadership in corporate strategy, business development, and licensing to Alnylam. His experience at a major pharmaceutical company like Sanofi suggests a focus on advancing Alnylam's pipeline through strategic partnerships, collaborations, and potentially M&A activities, which are critical for growth in the biotech sector.

Dr. Gros will receive an annual base salary of $425,000, a $200,000 sign-on bonus, and an additional $100,000 bonus payable after his first year. He is also eligible for an annual cash bonus (targeted at 40% of base salary) and has been granted stock options for 140,000 shares with a vesting schedule over four years.

Dr. Gros' stock option award for 140,000 shares vests over four years. 25% of the shares vest on the first anniversary of the grant date, and the remaining shares vest ratably over the following three years on a quarterly basis.

Yes, the offer letter includes provisions for repayment of the sign-on bonus and the subsequent bonus. If Dr. Gros voluntarily terminates his employment or is terminated for cause within twelve months of receiving the initial bonus, he must repay it. Similarly, the subsequent bonus must be repaid if he leaves within months twelve through twenty-four of his employment start date.